[Treatment of high-risk leukaemia: allograft and immunotherapy]

Fanny Rialland-Battisti; Marie Audrain

doi:10.1016/j.revinf.2019.09.002

[Treatment of high-risk leukaemia: allograft and immunotherapy]

Rev Infirm. 2019 Nov;68(255):16-18. doi: 10.1016/j.revinf.2019.09.002.

[Article in French]

Authors

Fanny Rialland-Battisti¹, Marie Audrain²

Affiliations

¹ Service onco-immuno-hématologie pédiatrique, centre hospitalier universitaire de Nantes, 7 quai Moncousu, 44093 Nantes cedex 1, France. Electronic address: fanny.rialland@chu-nantes.fr.
² Service onco-immuno-hématologie pédiatrique, centre hospitalier universitaire de Nantes, 7 quai Moncousu, 44093 Nantes cedex 1, France.

PMID: 31757321
DOI: 10.1016/j.revinf.2019.09.002

Abstract

Leukaemia results from a malignant proliferation of cells in the bone marrow. The prognosis is defined by the disease's biological characteristics. Treatment is based on chemotherapy. In cases of high-risk leukaemia, an allograft may be proposed. The arrival of targeted therapies and immunotherapy has revolutionised the prognosis of the disease. The challenge of the next few years will be to define the place of these therapies.

Keywords: allograft; allogreffe; bone marrow; graft; greffon; immunotherapy; immunothérapie; leucémie à haut risque; leukaemia; moelle osseuse.

MeSH terms

Allografts
Bone Marrow Transplantation*
Humans
Immunotherapy*
Leukemia* / therapy
Prognosis